While it is well worth considering the different groups that own a company, there are other factors that are even more important. But engineering living cells is hard-evolution is four billion years ahead of us, after all. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. According to the average forecast, sales growth in current quarter could jump down -50.50%, compared to the corresponding quarter of last year. Learn how were using our platform to create a growing ecosystem of collaborators. Ginkgo Bioworks made its highly anticipated stock-market debut Friday after closing its merger with a special purpose acquisition company. The company's corn-based feed additive, GRAINZYME Phytase, is just the first of many products that will benefit producers of poultry, swine, dairy and beef cattle, and aquaculture. Notably, sometimes top-level managers are on the board themselves. naar Get in touch with us directly. Ginkgo Bioworks Holdings Inc. (NYSE: DNA): What Matters Now We are sorry for the inconvenience. Hence, if weakness in Ginkgo Bioworks Holdings' share price continues, institutional investors may feel compelled to sell the stock, which might not be ideal for individual investors. Who Wins And Who Loses With China's Metal Restrictions, 3 Large Semiconductor Makers Offering Dividends & Price Growth, Fortinet Positioned For Growth In AI-Based Cybersecurity Boom, Three AI Trades That Could Double This Year, 2 Airlines Whose PE Ratios Scream Good Value. Customers Ginkgo Bioworks has not claimed their Profile. See what's happening in the market right now with MarketBeat's real-time news feed. Denali Therapeutics' return on equity of -40.01% beat Ginkgo Bioworks' return on equity. Isobionics, founded in 2008 by Toine Janssen, is an ingredients company in the Netherlands developing, producing and selling a range of natural products in the flavour and fragrance market using its proprietary platform technology This technology can produce many compounds such as: citrus oils (Lemon, Orange, Grapefruit), compounds like Valencene and Nootkatone, Menthol, Sandalwood oil, Patchouli oil, and many other less known basic building blocks for the Flavour & Fragrance industry. Producing Cultured Ingredients with Robertet, Protecting the worlds most valuable technology with IARPA, Building a Global Immune System with Concentric. Further, Ginkgo Bioworks Holdings Inc. (DNA) has a beta value of 1.00, and an average true range (ATR) of 0.14. Ginkgo Bioworks - Owler Arcaea, LLC (Ar-kay-uh), a company launched on the Ginkgo Bioworks platform, with the mission to build a new foundation for the beauty industry through expressive biology. By treating the genome as the unit of engineering, enEvolv offers substantial advantage in speed, cost, and cellular engineering capabilities. Willow Biosciences (TSX: WLLW) (OTCQB: CANSF) provides a research platform that reinvents the production of active pharmaceutical ingredient (API) supplies for global p. Analysts are projecting the companys earnings per share (EPS) to be -$0.08, which is expected to increase to -$0.05 for fiscal year -$0.35 and then to about -$0.23 by fiscal year 2024. Meanwhile, the second and third largest shareholders, hold 11% and 7.9%, of the shares outstanding, respectively. Currently, Ginkgo Bioworks Holdings Inc does not have a price-earnings ratio. It offers Color Test for patients to detect hereditary cancers such as brea, RedLeaf Biologics uses RedLeaf to produce natural food colors, and antioxidants for human and livestock applications. Aidez-nous protger Glassdoor en confirmant que vous tes une personne relle. Examples are nutraceuticals, flavors, fragrances, feed additives, intermediates and more. The Life Factory: Synthetic Organisms From This $1.4 Billion Startup Here's what their competitors are saying: G Algal Bio claims to be a better solution than Ginkgo Bioworks due to: Our biofoundry is solely focused around algae rather than microorganisms as other companies focus on. For the chemical industry, enzymes are important tools that make and break chemical bonds. Lygos' technology goes beyond engineering microbes and includes fermentation and purification development. I generally consider insider ownership to be a good thing. an. CBI websites generally use certain cookies to enable better interactions with our sites and services. Central to our technology is Antha, an operating system for biology which allows us to rapidly develop robust, high yielding bioprocesses to make bio-based products with our strategic partners. Developing great enzymes required both expertise and infrastructure. Ginkgo Bioworks Competitors and Alternatives 2023 (NYSE:DNA) - MarketBeat According to companys latest data on outstanding shares, there are 1.91 billion shares outstanding. Optimizing Crucial Drug Manufacturing of APIs with Merck, Introducing: Bioworks7 Mammalian Screening at Scale, Acquiring Altar and Circularis to Strengthen Our Capabilities. Normally microbes divide into two identical twins. Similar companies to Ginkgo BioWorks | VentureRadar And institutional investors endured the highest losses after the company's share price fell by 4.8% last week. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. In the meantime, 1 analyst(s) believe the stock as Underweight and 1 think it is a Sell. See insights on Ginkgo Bioworks including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. The Organism Company - Ginkgo Bioworks The company management answer to the board and the latter should represent the interests of shareholders. Thank you to Katia Tarasava for additional research and reporting on this article. Sign up here. Founded in 2010, Lygos is providing biotechnology solutions for todays renewable chemical challenges. As you can see, institutional investors have a fair amount of stake in Ginkgo Bioworks Holdings. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. They analyze gene sequences from public and proprietary databases and use predictive models to write new enzyme sequences. Impossible Foods sues Ginkgo Bioworks over heme proteins report on analyst forecasts for the company, Navigating The Evolving Fintech Landscape, Halftime 2023: Kicking The Recession Down The Road, Returns On Capital Are A Standout For Super Micro Computer (NASDAQ:SMCI). Baillie Gifford & Co. is currently the largest shareholder, with 12% of shares outstanding. Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT,[3] headed by Jason Kelly. See our latest analysis for Ginkgo Bioworks Holdings. Our proprietary biotechnology platform allows us to create fermentation-based manufacturing processes and to engineer the enabling microorganisms that drive the efficient conversion of renewable feedstocks into chemicals. Ginkgo Bioworks Company Profile - Office Locations, Competitors - Craft Our Platform - Ginkgo Bioworks DOD Consultant's big 2024 prediction looks to be coming true, Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation, [BREAKING] Small Firm Develops World's First Anti-Aircraft Laser, Wall Street legend warns: "A new dawn is coming", WARNING: These 110 Banks Are Planning to Replace the U.S. Dollar, Why 2023 Could Kick Off a "Cash Frenzy" in Stocks. For example, during the pandemic, Ginkgo collaborated with Aldevron to improve the production of its vaccinia capping enzyme, a critical component used in the manufacturing of the COVID-19 mRNA vaccines. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. However, high insider ownership can also give immense power to a small group within the company. Barry Canton Sells 37,650 Shares of Ginkgo Bioworks Holdings, Inc With the market capitalization of Ginkgo Bioworks Holdings Inc. currently standing at about $3.66 billion, investors are eagerly awaiting this quarters results, scheduled for Aug 14, 2023 Aug 18, 2023. We aim to bring you long-term focused analysis driven by fundamental data. Intelligence Advanced Research Projects Activity, "Ginkgo Bioworks aims to keep growing with new building in Seaport", "With Designer Bacteria, Crops One Day Could Fertilize Themselves", "Boston Startup Raises $100 Million To Use Synthetic Biology To Design Microbes For Industry", "Bayer And Ginkgo Bioworks, A Startup, Aim To Make Crops Produce Their Own Nitrogen Fertilizer", "Ginkgo Bioworks opens production site for custom cells", "Ginkgo Bioworks raises $350 million fund for biotech spinouts", "Ginkgo Bioworks CEO Wants Biology to Manufacture Physical Goods", "Startup Novogy Acquired by Ginkgo Bioworks", "Ginkgo Bioworks Acquires Biotechnology Startup Novogy's Microbial Engineering Platform", "Biotech firm Ginkgo to merge with Harry Sloan-led SPAC in $17.5 billion deal", "Ginkgo Bioworks begins trading on the NYSE after completing SPAC merger", "Ginkgo Bioworks to Go Public with Over $1.6 Billion in Proceeds", "Baillie Gifford Just Bought Ginkgo Bioworks (DNA) Stock. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Using machine learning to design novel enzymes. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Ginkgo Bioworks buys two small biotech companies Conventional production strategies are facing natural limitations, caused by exhaustion of producing microbes, and genetic drift. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. In connection with the Closing, the Company will change its name to Ginkgo Bioworks Holdings, Inc. and the combined company's shares of Class A common stock and public warrants are expected to . Our data indicates that hedge funds own 11% of Ginkgo Bioworks Holdings. We apply the principles of human nutrition and biotechnology to produce scientifically tested, evidence-based ingredients with higher bioavailability and nutritional value for select patient populations. Institutional owners may consider drastic measures as Ginkgo Bioworks Twitter Here's Why", "Ginkgo Bioworks Signs Definitive Agreement to Acquire FGen AG, a leading bioengineering company and its proprietary ultra-high-throughput screening platform", "Ginkgo Bioworks Acquires Bitome, an Integrated Metabolite Monitoring Platform", "Ginkgo Buys Embattled Biotech Firm Zymergen For Paltry $300 Million", "Ginkgo and Bayer Sign Definitive Agreement to Build Agricultural Biologicals R&D Platform Capabilities", "Ginkgo Bioworks Acquires Adaptive Laboratory Evolution Company Altar", "Two Is Better Than One: Ginkgo Bioworks Acquires Altar and Circularis", Genetic Engineering and Biotechnology News, "Ginkgo Bioworks Acquires Circularis to Strengthen Capabilities in Cell and Gene Therapy", "Ginkgo Is Trying to Detect Future Man-Made Biological Threats", https://www.prnewswire.com/news-releases/ginkgo-bioworks-partners-with-boehringer-ingelheim-to-develop-breakthrough-therapies-for-hard-to-treat-diseases-301817422.html, https://en.wikipedia.org/w/index.php?title=Ginkgo_Bioworks&oldid=1162741272, Biotechnology companies of the United States, Companies listed on the New York Stock Exchange, Pages with non-numeric formatnum arguments, Short description is different from Wikidata, Articles with self-published sources from December 2022, Official website different in Wikidata and Wikipedia, Creative Commons Attribution-ShareAlike License 4.0, Tom Knight, Jason Kelly, Reshma Shetty, Barry Canton, Austin Che. The main competitors of Ginkgo Bioworks include Denali Therapeutics (DNLI), Vir Biotechnology (VIR), Krystal Biotech (KRYS), CRISPR Therapeutics (CRSP), Revolution Medicines (RVMD), Immunocore (IMCR), Vaxcyte (PCVX), ProKidney (PROK), Halozyme Therapeutics (HALO), and Immunovant (IMVT).
Memorial Day Baseball Tournament 2023 Utah, Army Working Capital Fund, When Was Watermelon Discovered, Articles G